Blog

BOCA RATON, FL / ACCESS Newswire / August 21, 2025 / Newsmax Inc. (NYSE:NMAX) (“Newsmax” or the “Company”) today announced the appointment of David Gandler, Co-Founder and Chief Executive Officer of FuboTV Inc. (FUBO) (“Fubo”), as a Director to the Company’s Board of Directors, effective immediately.

“We are excited to add David Gandler to the Newsmax Board of Directors,” commented Christopher Ruddy, CEO of Newsmax. ” David’s achievements as an entrepreneur in the streaming and media industries will bring fresh perspective as we continue to expand our global reach, including through our streaming service Newsmax+. His success in building Fubo from startup to a leading operator in the space demonstrates the visionary leadership that will help Newsmax reach new audiences in today’s rapidly evolving media landscape.”

Mr. Gandler joins the five existing members of the Newsmax Board of Directors including Chief Executive Officer Christopher Ruddy, U.S. Secretary of Labor Alex Acosta, Ambassador Nancy Brinker, Christopher Nixon Cox and Ambassador Paula J. Dobriansky.

“I have long admired and respected Christopher Ruddy and his principled approach to journalism,” said Mr. Gandler. “Today’s 24/7 news cycle demands media companies deliver trusted information rapidly and through multiple distribution channels. I look forward to working with Chris and his Board of Directors to unlock new opportunities for Newsmax that will deepen audience engagement and accelerate growth.”

David Gandler

David Gandler is Co-Founder and CEO of Fubo, whose global mission is to aggregate the best in TV, including premium sports, news and entertainment content, through a single app.

Fubo listed on the New York Stock Exchange in October 2020, just five years after its founding. Fubo has ranked among The Americas’ Fastest-Growing Companies by the Financial Times (2025) and Forbes’ Next Billion Dollar Startups (2019).

Prior to founding Fubo in 2015, David had a prolific advertising career with more than 15 years of video sales in local broadcast and cable TV within both the general and Hispanic market, including at Scripps Networks Interactive, Time Warner Cable Media Sales and NBCUniversal’s Telemundo Media.

Beyond Fubo, David is a prominent figure in global sports and media. Through Gandler Sports Group (GSG), David is the majority owner and board member of soccer team Leyton Orient F.C. (EFL League One) and is a former co-owner of Paris FC. He also serves on the board of directors of Bare-Knuckle Fighting Championship (BKFC) and is a member of the esteemed Paley Media Council.

David has been named among Sports Business Journal’s Power Players: Sports Streaming (2025), Goldman Sachs’ 100 Most Intriguing Entrepreneurs (2019) and Variety’s Dealmakers (2020, 2019).

About Newsmax

Newsmax Inc. is listed on the NYSE (NMAX) and operates, through Newsmax Broadcasting LLC, one of the nation’s leading news outlets, the Newsmax channel. The fourth highest-rated network is carried on all major pay TV providers. Newsmax’s media properties reach more than 40 million Americans regularly through Newsmax TV, the Newsmax App, its popular website Newsmax.com, and publications such as Newsmax Magazine. Through its social media accounts, Newsmax reaches 20 million combined followers. Reuters Institute says Newsmax is one of the top U.S. news brands and Forbes has called Newsmax “a news powerhouse.”

For more information, please visit Investor Relations | Newsmax Inc.

Forward-Looking Statements

This communication contains forward-looking statements. From time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Forward-looking statements can be identified by those that are not historical in nature. The forward-looking statements discussed in this communication and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. Newsmax does not guarantee future results, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking statements. Forward-looking statements should not be relied upon as predictions of future events. We are under no duty to update any of these forward-looking statements after the date of this communication to conform our prior statements to actual results or revised expectations, and we do not intend to do so. Factors that may cause actual results to differ materially from current expectations include various factors, including but not limited to our ability to change the direction of Newsmax, our ability to keep pace with new technology and changing market needs, the competitive environment of our business changes in domestic and global general economic and macro-economic conditions and/or uncertainties and factors set forth in the sections entitled “Risk Factors” in Newsmax’s Annual Report on Form 10-K for the twelve months ended December 31, 2024, Newsmax’s Quarterly Report on Form 10-Q for the three months ended March 31, 2025, and other filings Newsmax makes with the Securities and Exchange Commission. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Undue reliance should not be placed on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein.

Investor Contacts

Newsmax Investor Relations
ir@newsmax.com

SOURCE: Newsmax Inc.

View the original press release on ACCESS Newswire

NEW YORK CITY, NEW YORK / ACCESS Newswire / August 21, 2025 / New to The Street today announced the launch of its newest segment, Unstoppable Entrepreneurs, co-produced and hosted by acclaimed entrepreneur and journalist Dr. Dustin Plantholt (Hon). The series will spotlight trailblazing leaders who are driving innovation, building resilient businesses, and shaping the future of their industries.

Filming for the inaugural episode begins next week and will feature an exclusive lineup of entrepreneurs and executives, including:

• Riadh Bouaziz, Chairman & CEO, RKF Group

• Paul Ziv, VP, Technology & Operations, TruAge Solutions LLC

• Dr. Mart McClellan, President, Macro Wealth Management

• Tim Hafner, CEO & Founder, OpenServ

The Unstoppable Entrepreneurs series will broadcast nationwide across New to The Street’s expansive media platform – including as sponsored programming on Bloomberg, as well as across FOX Business, YouTube, and the company’s extensive digital and social channels.

Vince Caruso, Co Founder & CEO of New to The Street, commented:

“At New to The Street, our mission has always been to spotlight companies and leaders that move industries forward. With Unstoppable Entrepreneurs, we’re doubling down on that promise. Dustin brings a unique storytelling ability that connects with entrepreneurs on a deeper level, creating content that not only inspires but also informs. This series will be a must-watch for anyone who wants to understand the mindset of those building tomorrow’s businesses.”

Dustin Plantholt, Co-Producer and Host, added:

“Entrepreneurs are the lifeblood of innovation and progress. Each one has a story of perseverance, vision, and determination that deserves to be told. I’m honored to partner with New to The Street to bring these stories to life and share the lessons of truly unstoppable individuals with a global audience.”

With the launch of Unstoppable Entrepreneurs, New to The Street continues to expand its reputation as a leading financial and business media platform, delivering unique, TV-ready earned media content with unmatched reach across broadcast, digital, and outdoor.

About Dustin Plantholt

Dr. Dustin Edward Plantholt (Hon) is an acclaimed journalist, entrepreneur, and AI architect. A former Senior Editor at Forbes Monaco and known globally as “The Count of Monte Crypto,” he has interviewed more than 500 changemakers – from heads of state to innovators, athletes, and artists. Named to the Forbes 40 Under 40 list and knighted by multiple royal houses, he has also received international humanitarian awards for his service and storytelling. His new Bloomberg program, Unstoppable Entrepreneurs, continues his mission to spotlight the people and ideas shaping the future.

About New to The Street

Since 2009, New to The Street has been one of the longest-running U.S. and international sponsored and syndicated television brands. The platform has produced and broadcast more than 3,000 interviews, reaching millions of homes across FOX Business, Bloomberg, and other networks, while also distributing content to over 3.2M YouTube subscribers and a robust global social media audience.

Media Contact:
Monica Brennan
Monica@NewtoTheStreet.com

SOURCE: New To The Street

View the original press release on ACCESS Newswire

JERUSALEM, IL / ACCESS Newswire / August 21, 2025 / AppYea Inc. (OTCQB:APYP) today announced a strategic business pivot with the acquisition of Techlott Ltd.’s proprietary blockchain-based lottery and gaming platform. The transaction refocuses AppYea on the rapidly growing institutional lottery market, providing a complete, production-ready technology package engineered for enterprise deployments.

Why Techlott is a Game-Changer?

Techlott’s platform addresses the core weaknesses of legacy lottery systems-high costs, opacity, and slow scaling. Its Web3 architecture is built for today’s market:

• Engineered for Public Trust: The system puts governance and compliance at its core. It features on-chain draw logic, verifiable randomness, and an immutable audit trail-all essential for regulators and government ministries. This design helps build public trust by providing full transparency.

• Significantly Lower Operating Costs: Unlike legacy systems that rely on complex infrastructure and large back-office teams, Techlott’s design automates core workflows and reduces operational overhead. We project this can lead to up to significant lower operating costs for our partners.

• Security and Readiness: The platform’s smart contracts have passed an independent QuillAudits review with no high or medium-severity issues. The system has successfully processed over 212,000 test transactions under transparency review, validating its readiness for national-scale use.

• Built for Flexibility: The stack supports B2G, B2B, and B2C models, allowing for broad commercial deployment. It integrates with multiple blockchain networks and supports hybrid fiat-crypto payments.

Global Lottery Market: A Massive, Under-Digitized Opportunity

Independent market data consistently shows a very large and expanding market:

• Grand View Research: $353.29B (2024), forecast to reach $483.93B by 2030.

• Verified Market Research: $327.44B (2024), forecast to reach $402.42B by 2032.

With only ~16% of global lottery activity currently online, the market is poised for digital migration. Techlott’s platform is uniquely positioned to capture this significant opportunity.

Next Steps & Capital Markets

As part of the transaction, AppYea is aligning with Techlott’s team, with Techlott becoming a significant shareholder and gaining board representation. We will focus on:

1. Technology Integration & Commercialization: Rapidly integrating the platform and initiating go-to-market efforts focused on government and enterprise deployments.

2. Applying to uplist to a US Exchange: Advancing preparations for a potential uplisting application and related financing activities to support scaled operations.

Executive Commentary

Yakir Abadi, Chief Executive Officer, AppYea:

“This acquisition is the culmination of a clear strategy. We identified a gap in a multi-billion dollar market and acquired the technology to fill it. Regulators and ministries worldwide are seeking transparency and efficiency, and Techlott delivers exactly that. Our plan is simple and focused: integrate, sign anchor partners, and prepare for our next chapter on a major exchange.”

Mark Katzenelson, Founder, Techlott:

“After years of development and millions of dollars invested, our platform is ready for prime time. Teaming with AppYea gives us the public-market presence and governance needed to deploy our technology at institutional and national scale. This partnership is a catalyst for our growth.”

Eldar Edmond Grady, Chairman, AppYea:

“We are now a technology-driven company with a clear product, a solid execution plan, and a path to growth. Our focus is on disciplined delivery: bringing the technology to market, securing key contracts, and strengthening our capital structure to drive long-term value for our shareholders.”

Additional information on the transactions are provided in AppYea’s current report on Form 8-K filed with the Securities and Exchange Commission.

About Techlott Ltd.

Techlott Ltd. is a Cyprus‑incorporated technology company specializing in lottery and gaming platforms for regulated environments. Under the parties’ definitive agreements, AppYea is acquiring Techlott’s software (including source code), documentation, and related IP, positioned for institutional‑grade commercialization.

Safe Harbor Statement:

Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future performance of AppYea are subject to many factors including, but not limited to, the sufficiency or working capital to realize our business plans and new strategic direction, the going concern qualification in our financial statements, our ability to penetrate the new intended markets, our success in integrating the platform and initiating go-to-market efforts, our success in uplisting to a US exchange, the introduction of competitive products, the impact of any adverse litigation, commercialization and technological difficulties, and the other risks identified in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on April 15, 2025. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information, or otherwise.

Investor Relations Contact:
Golmidas Communications
Email: info@golmidas.com

SOURCE: APPYEA, Inc.

View the original press release on ACCESS Newswire

CAMBRIDGE, MA / ACCESS Newswire / August 21, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced its participation in the following upcoming investor conferences:

Morgan Stanley’s 23^rd Annual Global Healthcare Conference, on Monday, September 8^th at 10:00am ET

Bernstein Insights: Healthcare Leaders and Disruptors, on Thursday, September 25^th at 10:30am ET

A live webcast of each of these presentations will be available under “Events and Presentations” in the Investors section of the Moderna website.

investors.modernatx.com.

A replay of each webcast will be archived on Moderna’s website for at least 30 days following the presentation.

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Media Contacts

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire

Advanced Care Specialists is Bringing Not Just Medical Care, but True Advocacy

RACINE, WISCONSIN / ACCESS Newswire / August 21, 2025 / Advanced Care Specialists (ACS), Racine’s premier provider of multidisciplinary medical care, is proud to announce a renewed focus on helping injured workers with a streamlined, patient-first approach that’s changing the face of occupational injury treatment in Wisconsin.

The Problem: Delays, Denials, and Disjointed Care

Every year, countless Wisconsin workers suffer injuries on the job, ranging from repetitive strain and back pain to traumatic incidents and long-term occupational illnesses. Unfortunately, many face a frustrating road to recovery, especially federal workers trying to navigate the complex Department of Labor (DOL-OWCP) claims process. Between confusing paperwork, denied claims, and a lack of specialized medical support, injured workers are often left feeling overwhelmed and under-cared for.

That’s where Advanced Care Specialists steps in.

The Solution: Comprehensive, Coordinated Care Under One Roof

ACS provides a one-stop solution for injured workers, offering medical care, physical therapy, chiropractic services, joint injections, and advanced Class IV infrared laser therapy-all in one location. What truly sets them apart is their expertise in managing federal injury cases, guiding patients through CA-1 and CA-2 forms, coordinating with case managers, and even helping appeal denied claims. Their work conditioning programs are uniquely designed to get patients back to work stronger, safer, and fully prepared for the demands of their job.

As the only clinic in the state specializing in DOL-OWCP federal work injury claims, ACS offers a full-service solution for workers navigating the complex world of federal workers’ compensation. From initial injury reports (CA-1 and CA-2) to case management, appeals, and long-term treatment, ACS guides patients every step of the way. Helping patients recover faster, return to work safely, and regain quality of life.

“We believe injured workers deserve more than a Band-Aid fix. Our mission is to get them back to full strength, back to their lives, and back to work-safely and confidently,” said Dr. Nic Kampfer, Work Injury Specialist at ACS. “We’re not just treating injuries; we’re restoring function, dignity, and hope.”

Why ACS is Making Headlines:

• Unmatched Expertise: ACS is the only clinic in Wisconsin fully equipped to handle federal work injury cases through the Department of Labor’s Office of Workers’ Compensation Programs (OWCP).

• Comprehensive Care: Services include physical therapy, chiropractic care, massage therapy, joint injections, and Class IV infrared laser therapy, and more -all under one roof.

• Work Conditioning Programs: Tailored to each patient’s job and goals, ensuring a safe and sustainable return to work.

• Patient Advocacy: ACS empowers workers to know their rights-including the right to choose their doctor-and helps them cut through the red tape of injury claims.

Whether you’re a federal employee, postal worker, or anyone hurt on the job, ACS is your partner in recovery.

For more information, visit advancedcarespecialists.com/services/work-injury or call (262) 898-9000.

About Advanced Care Specialists
Advanced Care Specialists (ACS) is a multidisciplinary medical clinic proudly serving the Racine, Wisconsin community with a commitment to delivering high-quality, patient-centered care. ACS offers a wide range of services including primary care, physical therapy, chiropractic care, interventional pain management, advanced wound care, hyperbaric oxygen therapy, regenerative medicine, massage therapy, and specialized programs for work injuries and federal workers’ compensation (DOL-OWCP). With an integrated team of healthcare professionals and a focus on collaborative treatment, ACS is dedicated to helping patients achieve lasting relief, improved mobility, and better overall health. Whether recovering from injury, managing chronic conditions, or striving for wellness, ACS is a trusted partner in long-term care and healing. For more information, visit www.advancedcarespecialists.com or call (262) 898-9000.

Media Contact:
Hannah Kearney
Marketing & Communications
Advanced Care Specialists
Email: info@advancedcarespecialists.com
Phone: (262) 898-9000

SOURCE: Advanced Care Specialists

View the original press release on ACCESS Newswire

Esteemed expert in the regulation and development of biopharmaceuticals, with more than three decades of experience spanning government, industry, and academia

MIAMI, FL / ACCESS Newswire / August 21, 2025 / iTolerance, Inc. (“iTolerance” or the “Company”), an early-stage privately-held biotechnology company focused on the development of innovative regenerative medicines, today announced the appointment of Emily Shacter, Ph.D. to the Company’s Scientific Advisory Board. Dr. Shacter has been supporting CMC development for iTolerance since February 2024.

“We are honored to welcome Dr. Shacter to our Scientific Advisory Board. With decades of experience as a leader in the regulation and development of biopharmaceuticals, we believe the insight Dr. Shacter will be instrumental as we continue to transition to a clinical-stage company and advance our therapies as a potential cure for Type 1 Diabetes. This appointment further strengthens our ability to navigate complex regulatory pathways, potentially accelerate clinical translation and unlock the full potential of our pipeline. Additionally, Dr. Shacter’s addition to our Scientific Advisory Board reflects our steadfast commitment to investing in the talent and guidance for iTolerance that we believe is needed to become a leader in the rapidly evolving regenerative medicine market,” commented Anthony Japour, Chief Executive Officer of iTolerance.

Dr. Shacter added, “Throughout my career at the FDA and in industry, I have seen firsthand both the challenges and opportunities involved in developing complex biological products. iTolerance’s platform technology, with its potential to enable tissue, organoid, and cell therapies without the need for life-long immunosuppression, provides an opportunity to address a profound unmet need in the field. I look forward to applying my experience to help guide the Company’s scientific and regulatory strategy as it moves toward clinical translation.”

Dr. Shacter is an esteemed expert in the regulation and development of biopharmaceuticals who served for nearly two decades at in the Division of Therapeutic Proteins of the Office of Biotechnology Products in the FDA’s Center for Drug Evaluation and Research (CDER). Her FDA career focused on oversight of biochemical characterization, manufacturing and control of complex protein therapeutics, including biosimilars and breakthrough biologics. As former Chief of the Laboratory of Biochemistry in the FDA’s CDER, she oversaw the review of numerous INDs and BLAs, played a role in shaping regulatory policy and advancing the science of biologics review, ran a laboratory research program, and oversaw the research of the principal investigators in her group. The research carried out in her laboratory provided the expertise required to understand and regulate complex biological products. Since 2012, she has served as an independent consultant, advising biotechnology companies on scientific and regulatory strategy for biologic drug development.

Additional career highlights include:

• Served as an FDA scientific advisor to the World Health Organization (WHO) for the development of international biosimilar guidelines;

• Engaged in FDA advisory and leadership roles, including the CDER Biosimilars Review Committee, Follow-on Biologics Working Group, and various CMC policy development efforts;

• Served as an editor and board member for major scientific journals including Free Radical Biology and Medicine and Journal of Biological Chemistry;

• Was an invited speaker and organizer at over 50 national and international conferences focused on biologics regulation, biosimilars, and analytical science;

• Authored or co-authored over 75 peer-reviewed publications in fields including protein oxidation, cell regulation, immunology, and cancer biology; and

• Received multiple FDA awards including the CDER Excellence in Mentoring Award and Center for Biologics Evaluation and Research Scientific Achievement Award for Excellence in Laboratory Science.

In addition to her decorated career in government and industry, Dr. Shacter’s research made significant contributions to understanding the molecular mechanisms of apoptosis, particularly in the context of cancer and inflammation. Her work focused on how reactive oxygen species produced during inflammation-such as hydrogen peroxide and taurine chloramine-affect the ability of chemotherapy drugs to induce apoptosis in cancer cells. She discovered that oxidative stress can inhibit both tumor cell death and the immune clearance of dying cells, and that antioxidants can restore chemotherapy efficacy. Dr. Shacter also identified the actin-regulating protein cofilin as a key intracellular redox sensor whose oxidation triggers mitochondria-dependent apoptosis. Additionally, she uncovered a novel role for the anticoagulant protein S in promoting macrophage phagocytosis of apoptotic cells. These findings provided critical insights into the interplay between inflammation, oxidative stress, and cell death, with implications for improving cancer therapies.

Dr. Shacter holds a Ph.D. in Biochemistry from Johns Hopkins University, completed in partnership with the National Institutes of Health, and a B.Sc. in Zoology from the University of Maryland.

About iTolerance, Inc.

iTolerance is a regenerative medicine company developing technologies to enable tissue, organoid or cell therapy without requiring life-long immunosuppression. Leveraging its proprietary biotechnology-derived Streptavidin-FasL fusion protein/biotin-PEG microgel (SA-FasL microgel) platform technology, iTOL-100, iTolerance is advancing a pipeline of programs using both allogenic cadaveric and stem cell-derived pancreatic islets to potentially cure Type 1 diabetes. Utilizing iTOL-100 to induce local immune tolerance, the Company is developing its lead indication as a potential cure for Type 1 Diabetes without the need for life-long immunosuppression. Additionally, the Company is developing iTOL-201 for treating liver failure by utilizing hepatocytes and iTOL-401 as a nanoparticle formulation for large organ transplants without the need for life-long immunosuppression. For more information, please visit itolerance.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. When used herein, words such as “anticipate”, “being”, “will”, “plan”, “may”, “continue”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking.

All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, anticipated levels of revenues, future national or regional economic and competitive conditions, and difficulties in developing the Company’s platform technology. Consequently, forward-looking statements should be regarded solely as the Company’s current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. The Company cannot guarantee future results, events, levels of activity, performance or achievements. The Company does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

Investor Contact
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
iTolerance@jtcir.com

Media Contact
Susan Roberts
T:202.779.0929
sr@roberts-communications.com

SOURCE: iTolerance, Inc.

View the original press release on ACCESS Newswire

HARRISBURG, PENNSYLVANIA / ACCESS Newswire / August 21, 2025 / Crump Life Insurance Services, one of the nation’s largest insurance wholesalers, recently announced that Caroline “Carly” Brooks, JD, CLU^©, CFP^©, has joined the organization leading their Advanced Sales team.

“Advanced sales is one of the cornerstones of our offering to the financial professionals we serve, and we are thrilled to have Carly join our team to lead this critical function for us,” said Mike Martini, President and CEO of Crump Life Insurance Services.

Brooks joins Crump as Senior Vice President and will lead Crump’s team of advanced sales specialists who focus on complex concepts and strategies within estate, wealth, and retirement planning. Bringing well over a decade of industry experience, Brooks most recently served as AVP and Counsel, Head of Advanced Markets for John Hancock Financial. Prior to John Hancock, she served in roles in wealth strategies and financial planning, progressing through positions of increasing responsibility. She is a frequent speaker at industry conferences and events and holds several positions on industry and legal boards and committees.

“The excitement from both our Crump teammates and our external clients about Carly joining Crump is palpable,” said Rob Stern, Chief Administration Officer for Crump who has oversight for advanced sales. “Carly has an impressive track record and has made a name for herself as a leading voice in the advanced markets space. We know Carly will be a great complement to the strong skills and knowledge within our advanced sales team. Carly’s passion and purpose coupled with Crump’s resources and carrier and client relationships position us for continued growth and success.”

About Crump

Crump Life Insurance Services is a leading third-party distributor and service provider of insurance and retirement products. Crump supports the distribution of traditional and variable life, annuity, long term care, linked benefits, disability, and health products with the industry’s premier sales and back-office support and technology services, marketing under the following brands: Truist Life Insurance Services, Tellus, and Hanleigh.

Contact Information

Jane DeMuth
Vice President, Marketing
jane.demuth@crump.com
717-736-7967

SOURCE: Crump Life Insurance

View the original press release on ACCESS Newswire